Protein therapy delivers to the body what it unfortunately
lacks in those who possess a variety of illnesses. It is a medical treatment
that has extensive healing possibilities currently being developed in many
highly visible fields such as cancer and other debilitating diseases.
Today, this medical treatment exhibits great promise for the
future as it is, for the most part, still in development and exploratory
stages. The concept is similar to yet also unlike gene therapy in that protein
therapy delivers protein to the body in specific amounts in the way it would
ordinarily present itself to assist in repairing illnesses, treat pain or
remake structures. It is important to view what we know today about protein
therapy in an investigational context; however researchers and scientists
indeed regard it with hope, as early studies have produced numerous benefits in
many cases.
Adding to the promise of protein therapy research and
development is Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage
biotechnology company that has been focusing on the discovery and development
of protein therapeutics that block cancer and inflammatory disease processes
since 2001.
FPRX’s product candidates include FPA008, an antibody that
inhibits colony stimulating factor-1 receptor. The antibody is in Phase Ib
clinical trials aimed at the treatment of rheumatoid arthritis and in pre-IND
stage for pigmented villonodular synovitis and several cancers in combination
with nivolumab.
Among the company’s numerous other candidates includes its
work in the area of immune-oncology. As of late, immuno-oncology has surfaced
as one of the most promising and fastest growing areas of cancer research and
drug development. FPRX’s protein discovery model is well-suited to identify novel
targets for the development of next generation immuno-oncology therapeutics.
Five Prime’s library, made up from more than 100 different
human tissues, comprises more than 5,700 structurally complete and biologically
active human proteins. The company feels this represents all of the body’s
medically important targets for protein therapeutics and is a deep source of
potential future protein drugs. Five Prime’s proprietary screening technology
enables it to identify ligand and receptor pairs, which is necessary for the
treatment of certain diseases at the highest levels.
Five Prime Therapeutics’ exciting progress does not come
without pursuit and execution of collaborative agreements with industry
leaders. It has a license and collaboration agreement with GlaxoSmithKline LLC,
Bristol-Myers Squibb Company and UCB Pharma S.A. Other efforts are made
possible with license agreements with Galaxy Biotech LLC, The Regents of the
University of California, BioWa, Inc., The Board of Trustees of Leland Stanford
Junior University, National Research Council of Canada and Lonza Sales AG.
For more information on the company, visit www.fiveprime.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
